CIPH Ciphergen Biosystems (MM)

Over 250 New Proteins Were Identified Which Could Represent Future Novel Biomarkers for Disease Detection Through Noninvasive Collection Methods FREMONT, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today in a paper published on-line in Journal of Proteome Research that it has identified an additional 251 proteins in urine using its new Equalizer bead technology in conjunction with its' ProteinChip(R) System, bringing the total unique gene products identified so far in human urine to around 800 species. This novel approach for mining the "unseen proteome" exploits solid phase ligand libraries which capture the various species present in urine up to the saturation of the solid phase ligand library. This automatically results in a dilution of the more abundant species, with a concurrent concentration of the dilute and rare ones that would normally escape conventional detection methods. "For decades, clinical chemists like me have been focused on new technologies to find and catalog new relevant protein biomarkers in body fluids that improve disease detection," said Professor Pier Giorgio Righetti, Polytechnic Institute, Milan, Italy and author of this paper. "Given this dramatic increase in the number of proteins discovered in urine (more than 200 new gene products never reported before) based on Ciphergen's new Equalizer bead technology, our dream might not be too far from fruition." "Equalizer bead technology can significantly expand exploration of various proteomes for biomarker discovery to enable applications in translational research and clinical diagnostics," stated William E. Rich, Ph.D., Chief Executive Officer of Ciphergen. Professor Pier Giorgio Righetti has been a true pioneer in proteome analysis. He has authored more than 700 scientific publications and two books on Proteomics with the last one released into press in 2005. He plays a significant role in the international proteomics organizations. Professor Righetti has recently been appointed to lead a new avant-garde facility and research group in proteome analysis at the prestigious Polytechnic School of Milan, Italy. About Ciphergen Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the ability of the Equalizer technology to detect unique proteins that can serve as biomarkers of disease and give a greater understanding of disease mechanism. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the Equalizer and ProteinChip technologies' ability to successfully discover, validate and assay biomarkers and patterns of biomarkers that are highly predictive and therefore meet with customer acceptance, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated August 9, 2005, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2233 Web site: http://www.ciphergen.com/

Copyright